Pox viruses are an exciting potential modality for the delivery of vaccines and the treatment of cancer, but their development and manufacture remain challenging. Ascend offer end-to-end Pox virus development and manufacturing services built on extensive experience and compliant with the specific regulatory requirements of this virus type.
The size of pox viruses prevents standard sterile filtration, requiring aseptic processing from start to finish in specialized BSL-2 facilities.
Pox virus manufacture requires an infection based, adherent culture approach
Laboratory personnel working directly with orthopoxviruses (including Pox viruses) are recommended to receive vaccination (Link)
Pox viruses, particularly modified vaccinia viruses, are being developed as oncolytic therapeutic agents that selectively infect and destroy cancer cells while stimulating anti-tumor immune responses.
These engineered viruses can be designed to carry foreign antigens, therapeutic genes or immune-stimulating factors, making them promising platforms for combination cancer immunotherapy approaches, as well as vaccination vectors.
However, the nature of these viruses present a number of specific challenges for developers.
Ascend is uniquely positioned to support your Pox virus development with a vaccinated, experienced workforce, proven manufacturing technologies and expertise in aseptic processing and closed-system development.
Please contact us using the form below and a member of our team will be in touch.
"*" indicates required fields
